Welcome

Welcome to the seventh issue of the ROADMAP newsletter!

This seventh newsletter marks the initiation towards the end of ROADMAP Phase 1, which will conclude at the end of October.

We had a great journey throughout the last two years. This project has probably been the most detailed and comprehensive evaluation of real-world evidence in Alzheimer's disease that has ever been conducted. Our teams have made great progress and findings of this fantastic work are now in the publication pipeline.

This newsletter includes an update on the progress of our work streams and links up some of the activities since the previous issue. Furthermore, our Consortium looks forward to lead exciting presentations as part of the “Real-world evidence in Alzheimer’s disease” sessions, including a plenary talk and four parallel sessions at this year's Alzheimer Europe Conference in Barcelona, so make sure to have a look at the events section.

Enjoy the read!

John Gallacher

Project Coordinator, Director of the MRC Dementia Platform UK and Professor of Cognitive Health at the University of Oxford

Understanding the implications of an integrated data environment

Interview with ROADMAPs Ethical, Legal and Social Implication team

What is the key output of the Ethical, Legal and Social Implication (ELSI) team going to be?
How ensure that the perspectives of people with dementia are considered?

Dr Zuzanna Angehrn and Dr Andrew Turner have been co-leading the ELSI team and brought perspectives from public and private sectors together, ensuring that personal information for scientific research are used for overall benefit, without affecting patients’ privacy or dignity.

ROADMAP progress update

The success of a project like ours relies on good communication, coordination and passionate members striving towards a common goal – improved healthcare. Here we give you an overview of the latest progress.

The value of an Expert Advisory Group

An online survey of ROADMAP Expert Advisory Group (EXAG) members and members of the Consortium was undertaken by Work Package 6 to evaluate how well the EXAG had supported HTA and regulatory engagement in the ROADMAP project and to assess the impact of the EXAG’s feedback on ROADMAP outputs and activities.

New deliverables

Catalogue of relevant AD models now public and available for download

Outcome Definition team submits priority RWE outcome list & disease classification matrix to IMI

Our Outcome Definition team has conducted a range of research, public involvement and review activities using a variety of sources and methods in order to define a list of priority outcomes that are of most relevance to key stakeholder groups, and to produce a disease progression and outcomes classification matrix that identifies priority outcomes at each stage of disease severity.

ROADMAP journey at Alzheimer Europe's Conference

On 30 and 31 October, ROADMAPs journey during the initial Phase 1 of the project will be featured at Alzheimer Europe’s 27th Conference “Making dementia a European priority” in Barcelona (Spain). This will entail a plenary talk by our Project Coordinator, John Gallacher, as well as four parallel sessions, encompassing participants from numerous Consortium partners, representatives from the European Working Group of People With Dementia, as well as members from ROADMAPs Expert Advisory Group.

Women and Dementia session at Alzheimer's Disease International Conference

On 27 July, Claire Tochel from the ROADMAP Consortium participated in a parallel session dedicated to research on women and dementia at the Alzheimer’s Disease International (ADI) Conference 2018. This symposium brought together a multidisciplinary group of experts and contributed a comprehensive discussion on female caregivers and dementia.

This section is dedicated to provide you direct access to detailed updates on all upcoming external ROADMAP presentations.

For an overview of upcoming events, visit our website.

Stay up-to-date on ROADMAP events

What we are reading

Regulatory science Newsletter
20 July 2018 (CBG/MEB)

Regulatory science provides the Medicines Evaluation Board (MEB) with up-to-date data, knowledge and expertise based on current scientific insights...Read more

Big Data for Better Outcomes Newsletter

6 September 2018 (BD4BO)

The BD4BO mission is to improve health outcomes and health care systems in Europe by maximising the potential of big... Read more

ROADMAP

is a part of the Big Data for Better Outcomes (BD4BO) programme.

Copyright © 2018 ROADMAP, All rights reserved.

Our mailing address is:
info@roadmap-alzheimer.org
Sign up for our list!
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This email was sent to <<Email Address>>
why did I get this? unsubscribe from this list update subscription preferences
ROADMAP · Alzheimer Europe · 14 rue Dicks · Luxembourg L-1417 · Luxembourg